18F-FDG PET/CT Findings in Pancreatic Carcinoma and Their Diagnosis Value
WANG Zhong-qiu,LU Guang-ming,ZHU Hong,CHANG Lin-feng,WU Jiang,ZHENG Ling,WANG Jun-peng,QIN Li-ping
DOI: https://doi.org/10.3969/j.issn.1008-8199.2006.04.020
2006-01-01
Abstract:Objective:To describe the findings and to assess the diagnosis value of positron emission tomography/computed tomography (PET/CT) with fluorine-18-labeled fluorodeoxyglucose (FDG) for pancreatic carcinoma. Methods: FDG PET/CT was performed in twenty six patients having pancreatic malignent neoplasm and six patients having pancreatitis, all proved by comprehensive methods as surgery and clinical diagnosis. Images were interpreted and compared with the histopathologic findings at surgery or with clinical follow-up findings. The sensitivity, specificity and accuracy of PET/CT diagnosis were analyzed. Results: Twenty six patients had pancreatic malignant neoplasm, among whom 20 were pancreatic carcinomas, 3 were postoperation recurrence of pancreatic carcinoma, 2 were metastatic carcinoma of pancreas and 1 was potential malignancy. Eight cases were metastatic in parapancreas and retroperitoneal lymph node, 4 in peritoneal cavity and mesentery, 7 in hepatic metastatic, and 2 in bone. The PET/CT findings of 26 patients with pancreatic malignant neoplasm showed that there were 21 in Type Ⅰ, 3 in Type Ⅱ, 2 in TypeⅢ and 0 in TypeⅣ, respectively. The sensitivity, specificity and accuracy of PET/CT diagnosis were respectively 96.2%,66.7% and 87.5%. Conclusion: Imaging demonstration of PET/CT for pancreatic carcinoma varies in modality, and Type Ⅰ (80.8%) was typical. PET/CT was of great value for the diagnosis of pancreatic carcinoma, although there were still a few false positive and false negative findings.